Pipeline
Programmes from discovery through marketed combination products.
Each programme pairs a device with a pharmaceutical to address a specific complication. Stages below reflect development status, not commercial availability in every market.
Cardiovascular
Paclitaxel-eluting coronary stent
The drug-coated stent platform that helped establish drug elution as a standard in cardiovascular medicine.
Indication: Coronary artery restenosis
Wound closure
Drug-carrying wound closure
Sutures and closure devices that carry an antimicrobial or anti-fibrotic agent directly into the incision line.
Indication: Surgical site complications
Interventional oncology
Localised oncology delivery device
A device-delivered depot that concentrates cytotoxic therapy at the tumour site during an interventional procedure.
Indication: Solid tumour adjunct therapy
Ophthalmology
Ocular sustained-release implant
A small implant delivering a precisely metered dose to ocular tissue over months, reducing injection frequency.
Indication: Chronic posterior segment disease
Biomaterials
Anti-fibrotic implant coating
A surface treatment that moderates the fibrotic response to long-term implants such as meshes and leads.
Indication: Implant encapsulation and fibrosis